Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Sorafenib in Advanced Salivary Adenoid Cystic Carcinoma
2008-000066-22Phase 2Completed
- Sponsor
- The Christie
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in adenoid cystic carcinoma (ACC), sponsored by The Christie. Primary endpoint: 12-month progression-free survival. Started Feb 2008; status: completed.
02
Drugs
sorafenib
03
Conditions
adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on 2008-000066-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000066-22.